This report covers the 68 geographical markets and provides an Excel-based forecast model for the Female Infertility market through 2033.
Across the 68 markets, sales in the Female Infertility market were $3.0 billion in 2023, growing to $4.4 billion in 2033.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 54.4% and 53.1% of 68-market sales in 2023 and 2033, respectively.
Across the 68 markets, sales in the Female Infertility market were $3.0 billion in 2023, growing to $4.4 billion in 2033.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 54.4% and 53.1% of 68-market sales in 2023 and 2033, respectively.
Scope
- This publication is an expanded version of the Excel model containing the patient-based forecast sales for Female Infertility, covered in the analyst’s report “Female Infertility: Seven -Market Drug Forecast and Market Analysis”, published in June 2024. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 60 geographical markets (60M), totaling 68 markets (68M).
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Female Infertility therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Female Infertility therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- About the Analyst
1.1 Overview
1.2 68M summary statistics
1.3 Key 7MM events driving the 68M forecast extrapolation
2 Appendix
2.1 Abbreviations
2.2 Methodology
2.2.1 Patient-based forecast methodology Error! Bookmark not defined
2.2.2 68M forecast extrapolation methodology. Error! Bookmark not defined
2.3 Primary research - key opinion leaders interviewed for this report
2.3.1 Key opinion leaders
2.4 Primary research - prescriber survey
2.5 About the authors
2.5.1 Analyst
2.5.2 Therapy area directors
2.5.3 Vice President of Disease Intelligence and Epidemiology
2.5.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Merck
- Novartis
- Sanofi
- Fuji Pharma
- Pfizer
- AstraZeneca
- Theramex
- Abbvie
- Gedeon Richter
- Sun Pharma
- Ferring Pharmaceutical
- IBSA
- Kissei
- Teva
- Organon
- Takeda
- TerSera
- MSD
- ASKA Pharmaceutical
- Allergen
- Juniper
- Schering-Plough
- Finox
- Neurocrine Biosciences
- EMD Serono
